Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
L-alanine transaminase (ALT), also known as alanine aminotransferase, is an enzyme that catalyzes the reversible transfer of an amino group from L-alanine to α-ketoglutarate, producing pyruvate and L-glutamate. ALT is predominantly found in the liver, making it a key biomarker for liver health. Elevated serum ALT levels are indicative of hepatocellular injury or liver disease. The enzyme requires pyridoxal phosphate as a coenzyme. While ALT itself is not directly targeted by drugs, its levels are monitored to assess the impact of drugs and other factors on liver function.
Not applicable - ALT is primarily a biomarker, not a direct drug target, though drugs can affect its levels through liver effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on L-alanine transaminase (ALT).